Craig Hallum Lowers Certara (NASDAQ:CERT) Price Target to $8.00

Certara (NASDAQ:CERT) had its price objective reduced by analysts at Craig Hallum from $10.00 to $8.00 in a report issued on Tuesday, Marketbeat.com reports. The firm currently has a “hold” rating on the stock. Craig Hallum’s price target would indicate a potential upside of 67.01% from the company’s previous close.

Several other research firms have also commented on CERT. Morgan Stanley reduced their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday. BMO Capital Markets reduced their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday. Robert W. Baird reduced their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday. Barclays reduced their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Certara presently has an average rating of “Hold” and a consensus target price of $8.85.

Certara Trading Down 5.9%

Shares of CERT opened at $4.79 on Tuesday. Certara has a 1-year low of $4.78 and a 1-year high of $13.88. The company has a 50-day moving average of $6.13 and a 200 day moving average of $7.91. The firm has a market capitalization of $745.18 million, a price-to-earnings ratio of -47.90 and a beta of 1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 2.05.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the previous year, the business earned $0.14 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, research analysts expect that Certara will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CERT. Wasatch Advisors LP raised its stake in shares of Certara by 45.7% during the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock worth $158,335,000 after acquiring an additional 4,244,230 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Certara during the 4th quarter worth approximately $26,706,000. Deerfield Management Company L.P. raised its stake in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after acquiring an additional 2,813,438 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in shares of Certara by 133.4% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after acquiring an additional 1,299,109 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Certara by 27.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after acquiring an additional 1,165,064 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Key Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara said its AI-related investments should support long-term growth, which could help investor confidence over time. Certara says AI investments will drive long-term growth – but traders are focused on one warning
• Neutral Sentiment: Certara announced expected 2026 revenue of $395 million to $405 million following its medical writing divestiture, giving investors a clearer forward outlook, though the range appears modest. Certara expects $395M-$405M 2026 revenue following medical writing divestiture
• Negative Sentiment: Several firms lowered price targets on Certara, including Morgan Stanley, Stephens, Craig Hallum, Barclays, and Robert W. Baird, signaling reduced near-term enthusiasm for the stock. Certara (NASDAQ:CERT) Price Target Lowered to $10.00 at Morgan Stanley
• Negative Sentiment: Analysts cut Certara’s valuation after the earnings update, with targets reduced to $9.00 from Stephens and $8.00 from Craig Hallum, reinforcing pressure on the shares. Certara (NASDAQ:CERT) Given New $9.00 Price Target at Stephens
• Negative Sentiment: Certara was said to have hit a new 52-week low after missing earnings expectations, highlighting investor concern about profitability. Certara (NASDAQ:CERT) Hits New 52-Week Low After Earnings Miss

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.